IDEXX Laboratories (IDXX) Q3 2026 Earnings
Q3 EPS included a $0.03 per share benefit from a non-operating gain on an equity investment, $0.01 per share in tax benefits from share-based compensation, and a $0.04 per share benefit from year-over-year currency changes, while absorbing acquisition impacts including transaction-related costs; company-reported comparable EPS was $3.96.
How Did IDXX Stock React to Q3 2026 Earnings?
Did IDXX Beat Earnings? Q3 2026 Results
Yes. IDEXX Laboratories reported Q3 2026 earnings of $4.01 a share on Nov 2, 2026, beating the $3.72 consensus estimate by 7.9%. Revenue was $1.2B against a $1.2B estimate.
IDEXX Laboratories delivered a strong third quarter of 2026, posting GAAP EPS of $4.01 against a consensus estimate of $3.72, a beat of 7.91% that extended the company's streak of exceeding consensus EPS estimates to seven consecutive quarters. Revenue of $1.21 billion rose 9.9% year over year, clearing the $1.19 billion consensus by 1.83%, as CAG Diagnostics recurring revenue, the company's core growth engine, climbed 11% both reported and organically. The result was powered by a 14% to 15% surge in VetLab consumables tied to an 11% expansion of the premium instrument installed base, alongside strong international momentum and U.S. volume growth the company said exceeded sector trends. GAAP EPS of $4.01 included a $0.03 per-share non-operating gain on an equity investment, $0.01 in share-based compensation tax benefits, and a $0.04 currency tailwind. Looking ahead, management raised full-year 2026 EPS guidance to $14.96 to $15.16 and lifted revenue guidance to $4.74 billion to $4.77 billion, reflecting continued organic momentum and the addition of CoVet, its recently acquired AI clinical assistant for veterinary teams.
- CAG Diagnostics recurring revenue grew 11% reported and organic, with International up 13% reported/14% organic and U.S. up 10%
- IDEXX VetLab consumables grew 14% reported and 15% organic on net new customers, 11% premium instrument installed base expansion, and new product utilization
- Reference lab revenue grew 10% on testing volume, new customers and price realization
- Over 1,900 inVue Dx placements in the quarter, installed base nearly 11,000
- Strong diagnostic imaging installations led by ImageVue DR50 Plus
- Gross margin up 110 bps to 62.9% on volume gains, productivity initiatives and net price realization
- Operating margin up 100 bps to 33.1%
“IDEXX delivered exceptional third quarter results, reflecting strong commercial execution and momentum from our innovation-driven growth strategy.”
IDEXX Laboratories CEO, on the earnings call
What Is IDEXX Laboratories's Outlook?
IDEXX raised its 2026 revenue guidance to $4,741M–$4,767M (prior $4,700M–$4,745M), up $32M at midpoint including $5M from CoVet. - Reported revenue growth: 10.1%–10.8%; organic growth: 9.3%–10.0%. - CAG Diagnostics recurring revenue growth: 11.0%–11.7% reported, 10.3%–11.0% organic. - Operating margin: lowered to 32.1%–32.3% (50–70 bps expansion) to reflect acquisition-related impacts. - EPS: raised to $14.96–$15.16 (prior $14.69–$14.94), or 14%–16% reported and 15%–16% comparable growth. - Other assumptions: net interest expense ~$32M, effective tax rate ~20.5%, ~2% reduction in average shares outstanding, and capex ~$160M. - Cash flow: operating cash flow at 110%–120% of net income and free cash flow at 95%–100% of net income. - Currency: FX expected to add ~0.7% to revenue growth and ~$0.25 to EPS.
IDXX YoY Financials
| Metric | Q3 2026 | Q3 2025 | Year over year |
|---|---|---|---|
| Revenue | $1.2B | $1.1B | +9.9% |
| Gross Profit | $764.3M | $683.3M | +11.9% |
| Operating Income | $402.3M | $354.8M | +13.4% |
| Net Income | $317.1M | $274.6M | +15.5% |
IDXX Revenue by Segment
IDXX Revenue by Geography
When Does IDEXX Laboratories Report Next?
Figures from SEC filings and company reports. Not investment advice.